Dr. Heng is the Division Head of Medical Oncology at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and trained at the BC Cancer Agency and Cleveland Clinic Taussig Cancer Institute. He has a Masters of Public Health from Harvard University. Dr. Daniel Heng leads the International mRCC Database Consortium (IMDC) which comprises of over 14,000 patients with metastatic renal cell carcinoma which has led to the creation of the IMDC prognostic criteria (a.k.a. Heng Criteria).